Medical experts specializing in acute lymphoblastic leukemia explore emerging trends and potential future developments for CAR T-cell therapy in treating relapsed or refractory B-cell ALL.
What are future directions for CAR T-cell therapy in r/r B-Cell ALL?
What unmet needs still exist in the treatment paradigm of r/r B-cell ALL?
Can each of you share any key takeaways or additional data updates that you would like to highlight surrounding r/r B-cell ALL presented at EHA 2024? (if time permits)